Panacea Biotec Ltd
Thu 10/07/2025,12:14:47 | NSE : PANACEABIO
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 421.00
Previous Close
₹ 418.80
Volume
103110
Mkt Cap ( Rs. Cr)
₹2509.14
High
₹ 423.00
Low
₹ 407.30
52 Week High
₹ 581.90
52 Week Low
₹ 130.00
Book Value Per Share
₹ 135.98
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Panacea Biotec Ltd
Your Vote -
Buy
92.82%
Hold
3.31%
Sell
3.87%
92.82%
181 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
32%
Sell Order Quantity
68%
Bid Price
Qty
409.55
2
410.00
27
409.00
25
409.00
14
409.00
55
Bid Total
28932
Bid Price
Qty
410.05
55
410.00
4
410.00
6
410.00
4
410.00
12
Bid Total
62191
Option Chain
Analyzes market sentiment, predicts Panacea Biotec Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Panacea Biotec L - Intimation Of Settlement Of Disputes With Apotex Inc., Canada\r\nUnder Regulation 30 Of SEBI (Listing Obli
-
Panacea Biotec L - Updates
-
Panacea Biotec L - Updates
-
Panacea Biotec L - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Panacea Biotec L - Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Pa
-
Panacea Biotec L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Panacea Biotec L - Disclosure under SEBI Takeover Regulations
-
Panacea Biotec L - Trading Window-XBRL
-
Panacea Biotec L - Trading Window
-
Panacea Biotec L - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Panacea Biotec L - Press Release
-
Panacea Biotec L - Copy of Newspaper Publication
-
Panacea Biotec L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Panacea Biotec L - Updates
-
Panacea Biotec L - Intimation Regarding Appointment Of Secretarial Auditor
-
Panacea Biotec L posts Q4 net loss of Rs 12.39 cr
-
Panacea Biotec L - Standalone And Consolidated Audited Financial Results Along With Auditors' Report For The Quarter And Fina
-
Panacea Biotec L - Outcome of Board Meeting
-
Panacea Biotec L - Outcome of Board Meeting
-
Panacea Biotec L - Board Meeting Outcome for 1. Standalone And Consolidated Audited Financial Results Along With Auditors' Re
-
Panacea Biotec L - Board Meeting Intimation
-
Panacea Biotec L - Board Meeting Intimation for For Approval Of The Audited Financial Results For The Quarter And Financial Y
-
Panacea Biotec L - Updates
-
Panacea Biotec L - Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) Confirms Chilrun Full Accelerate
-
Panacea Biotec L - Updates
-
Panacea Biotec L - Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) Of The SEBI (Depositories And Pa
-
Panacea Biotec L - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Panacea Biotec L - Bagging/Receiving of orders/contracts
-
Panacea Biotec L - Receipt Of An Additional Award From UNICEF For Supply Of Bivalent Oral Polio Vaccine (Bopv) Worth ~US$ 5.2
-
Panacea Biotec L has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Panacea Biotec gains on Rs. 127 crore contract from UNICEF
-
Panacea Biotec
-
Panacea Biotec launches Paclitaxel Protein-Bound Particles for Injectable Suspension
-
Panacea Biotec launches Paclitaxel Protein-Bound Particles for Injectable Suspension
-
Panacea Bio introduces Food & Nutritional Products
-
Panacea Biotec
-
Panacea Biotec up 9% on first shipment of second component of Sputnik V
-
Panacea Biotec up 9% on first shipment of second component of Sputnik V
-
Panacea Biotec receives licence to produce Sputnik V vaccine at Himachal Pradesh
-
Panacea Biotech
-
Panacea Biotec to consider fund raising plan
-
RDIF, Panacea Biotec launch the production of Sputnik V in India
-
Panacea Biotec to produce 100 million doses of Sputnik V
-
Panacea Biotec
-
Panacea Biotec announces successful completion of Phase I/II
-
Panacea Biotec collaborates with Refana for Covid-19 vaccine
-
Panacea up on signing agreement with Serum Institute
-
Panacea surges on getting USFDA approval
-
Panacea Biotec expands collaboration with US firm
Key fundamentals
Evaluate the intrinsic value of Panacea Biotec Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 542.42 | 454.009 | 428.102 | 499.249 | 570.247 |
| Liabilities | 542.42 | 454.009 | 428.102 | 499.249 | 570.247 |
| Equity | 6.13 | 6.125 | 6.125 | 6.125 | 6.125 |
| Gross Profit | -6.93 | 14.167 | -62.627 | -72.67 | 0.488 |
| Net Profit | -15.23 | 3.55 | -87.544 | -93.576 | -14.441 |
| Cash From Operating Activities | 3.94 | 37.273 | -10.742 | -52.69 | 38.266 |
| NPM(%) | -4.91 | 0.98 | -34.05 | -39.73 | -4.2 |
| Revenue | 309.85 | 359.604 | 257.067 | 235.504 | 343.555 |
| Expenses | 316.78 | 345.437 | 319.694 | 308.174 | 343.067 |
| ROE(%) | -1.82 | 0.42 | -10.51 | -11.23 | -1.73 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 19 Sep 2011 | 0.75 | 75 | 0 | 184.8 |
| 16 Sep 2010 | 0.25 | 25 | 0 | 225.1 |
| 19 Sep 2008 | 1 | 100 | 0 | 301.55 |
| 21 Sep 2007 | 1 | 100 | 0 | 424.4 |
| 22 Sep 2006 | 1 | 100 | 0 | 358.15 |
| 12 Aug 2005 | 1.5 | 150 | 0 | 144.8 |
| 13 Sep 2004 | 1 | 100 | 0 | 45.1 |
| 12 Sep 2003 | 1 | 100 | 0 | 34.5 |
| 13 Aug 2002 | 0 | 100 | 0 | 365.8 |
| 0 | 0 | 0 | 360.4 | |
| 07 Aug 2001 | 0 | 100 | 0 | 473 |
| 0 | 50 | 0 | 391.2 | |
| 0 | 50 | 0 | 224 | |
| 0 | 30 | 0 | 105.7 |
Peers
Other companies within the same industry or sector that are comparable to Panacea Biotec Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 912.65 | -0.93 | 30.28 | 240.79 | 301.39 | 0.55 |
| Lotus Eye Hospital and Institute Ltd | 73.90 | 0.07 | 211.14 | 877.40 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 12.77 | 0.08 | 212.83 | 452.24 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 899.85 | -1.55 | 0.00 | 827.40 | -601.21 | 0.00 |
Company Info
YEAR EVENTS 1984 - Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act, 1956 w.e.f. 30.6.93. - The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products. - The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry. 1993 - The name of the Company changed to Panacea Biotec Limited on 7th September. - The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions. 1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise. 1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's. 1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh. 1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries. 1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis. 2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration. - The company has proposed an amendment in articles of association for implementing the depository system for its stocks. - The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market. - Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake. - The company is setting up another plant at Lalru to manufacture branded formulations for the export market. - The company is planning to launch an anti-histamine drug in June this year. - Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products. - The Company has entered into agreement with NSDL and CDSL for dematerialisation. 2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology. 2002 -Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company. -Files for worldwide patent for its new NDDS for an anti-TB combination drug. -Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK. -Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital. -Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc. 2003 -Stock split from Rs 10 per equity share to Rs 1 per equity share - Panacea Biotec forays OTC market with Herbal Products 2004 -California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India -Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team. -Panacea rolls out new nimesulide injection -Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004 2005 -Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation -Panacea Biotec introduces Noval Anti-allergy Drug - Ralif 2006 -Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine 2007 - Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines 2009 - Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF 2010 - Panacea Biotech's Baddi unit gets US FDA approval - Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. 2011 - PanaceBiotec - Panacea Biotec Launches - PacliALL - Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana. 2012 - PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria". - Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria - PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit - PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical - Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines 2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries. 2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF. 2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth 2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib". 2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc. 2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market. 2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies. 2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India. 2022 -Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines. 2023 -Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany. - Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane. -Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '. 2024 -The Company has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.
YEAR EVENTS 1984 - Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act, 1956 w.e.f. 30.6.93. - The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products. - The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry. 1993 - The name of the Company changed to Panacea Biotec Limited on 7th September. - The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions. 1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise. 1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's. 1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh. 1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries. 1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis. 2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration. - The company has proposed an amendment in articles of association for implementing the depository system for its stocks. - The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market. - Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake. - The company is setting up another plant at Lalru to manufacture branded formulations for the export market. - The company is planning to launch an anti-histamine drug in June this year. - Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products. - The Company has entered into agreement with NSDL and CDSL for dematerialisation. 2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology. 2002 -Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company. -Files for worldwide patent for its new NDDS for an anti-TB combination drug. -Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK. -Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital. -Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc. 2003 -Stock split from Rs 10 per equity share to Rs 1 per equity share - Panacea Biotec forays OTC market with Herbal Products 2004 -California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India -Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team. -Panacea rolls out new nimesulide injection -Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004 2005 -Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation -Panacea Biotec introduces Noval Anti-allergy Drug - Ralif 2006 -Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine 2007 - Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines 2009 - Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF 2010 - Panacea Biotech's Baddi unit gets US FDA approval - Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. 2011 - PanaceBiotec - Panacea Biotec Launches - PacliALL - Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana. 2012 - PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria". - Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria - PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit - PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical - Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines 2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries. 2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF. 2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth 2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib". 2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc. 2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market. 2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies. 2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India. 2022 -Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines. 2023 -Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany. - Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane. -Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '. 2024 -The Company has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.
Read More
Parent Organisation
Panacea Biotec Ltd.
Founded
02/02/1984
Managing Director
Dr.Rajesh Jain
NSE Symbol
PANACEABIOEQ
FAQ
The current price of Panacea Biotec Ltd is ₹ 409.65.
The 52-week high for Panacea Biotec Ltd is ₹ 423.00 and the 52-week low is ₹ 407.30.
The market capitalization of Panacea Biotec Ltd is currently ₹ 2509.14. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Panacea Biotec Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Panacea Biotec Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Panacea Biotec Ltd shares.
The CEO of Panacea Biotec Ltd is Dr.Rajesh Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
